Impact of COX Inhibition on Cholesterol Transport in Macrophages
Author Information
Author(s): Chan Edwin SL, Zhang Hongwei, Fernandez Patricia, Edelman Sari D, Pillinger Michael H, Ragolia Louis, Palaia Thomas, Carsons Steven, Reiss Allison B
Primary Institution: New York University School of Medicine
Hypothesis
Downregulation of cholesterol efflux proteins contributes to increased cardiovascular risk associated with COX inhibition.
Conclusion
COX inhibition reduces the expression of cholesterol transport proteins, potentially increasing cardiovascular risk.
Supporting Evidence
- COX-2 inhibitors have been linked to increased cardiovascular events.
- Downregulation of cholesterol 27-hydroxylase and ABCA1 was observed with COX inhibition.
- Foam cell transformation was significantly increased in the presence of COX inhibitors.
Takeaway
When certain medications that block COX enzymes are used, they can lower the levels of proteins that help remove cholesterol from cells, which might lead to heart problems.
Methodology
The study involved culturing THP-1 human monocytes/macrophages and assessing the effects of COX inhibitors on cholesterol transport protein expression and foam cell transformation.
Potential Biases
Potential bias in the selection of experimental conditions and reagents.
Limitations
The study was conducted in vitro, and results may not fully translate to in vivo conditions.
Participant Demographics
THP-1 human monocytes/macrophages were used as the model system.
Statistical Information
P-Value
0.04
Confidence Interval
95% CI 1.19 to 3.11
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website